Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
# v) t/ ?: |1 H$ ^6 L
& ?3 p+ |- Y3 D R
V* t( x# J: C. t4 \' iSub-category:# _% F; {# D4 g
Molecular Targets
! z8 P# M: [ m1 W, F. \" ~& I4 ~) a) m
) o. P6 @4 E' i5 sCategory:
4 @# i0 c; u' D" sTumor Biology
$ i% Z6 y" ~7 H2 k& @
" M$ k* {/ e, V! Z/ S
5 q& I3 C3 x' ^( Z# U, f) DMeeting:- Q9 ?' y% ` ^) G. E
2011 ASCO Annual Meeting . t' |7 {1 q- V
" r" G* e3 {1 [3 w5 H9 m
r- i/ D) I- ~0 q' u7 N( E9 ^Session Type and Session Title:4 d* M4 @: r- X
Poster Discussion Session, Tumor Biology * j4 K: G* y3 B
r% M9 F8 ]) ]. ^4 A" x8 u, J4 h4 ?( h4 ]: e" {5 y; X
Abstract No:9 O [( ?, f# |/ k+ d, d$ J' z
10517 ! }; i7 `* B0 k2 p5 w: B+ J/ H
8 g6 N9 ]* R6 J w5 I* x9 Q2 t( n" Z9 D
Citation:) o/ [$ Q0 x4 j
J Clin Oncol 29: 2011 (suppl; abstr 10517)
) V" o8 W; I% o- A4 t' Y- r! m2 ^- _" D- o) P6 e2 W
4 j0 S4 ~' m9 G+ p9 ^) E. ^Author(s):1 p, u/ s0 Y' X1 @( `
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 v( K ]9 V) t( T' _" G' J. D
3 K7 T" ]! f b i, s# g8 C% \
, ]& w |3 E1 |7 y( y8 g: v8 G- a: w% H2 O$ P2 M
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.5 [7 ^) ^* j0 Z* k* J/ J M
" ~& f8 g" W6 ], h! K( a- G/ bAbstract Disclosures% I: L7 I# O4 A0 A4 |( n' W
$ `$ G, y3 T# ^ W; l3 PAbstract:
3 w5 o1 W4 x+ {( ?& C. M! l3 U4 K* A& E0 L9 x( T! ?
( U2 f4 {% d/ x+ }4 }+ NBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
9 c7 l+ I% y& u
7 s7 x Z$ H) ~3 c- s7 U( R, V1 e
' N1 d6 C" x: _0 M |
显身卡
